Patients with EGFR-mutated NSCLC who have progressed after multiple lines of therapy may have meaningful and durable responses to a novel antibody-drug conjugate HER3-DXd, new phase 2 data suggest.
Patritumab deruxtecan displayed clinically meaningful and durable efficacy in patients with advanced EGFR-mutated non–small cell lung cancer who experienced progression following treatment with an EGFR-directed TKI and platinum-based chemotherapy.